Equities Analysts Set Expectations for ARWR FY2025 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Analysts at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for shares of Arrowhead Pharmaceuticals in a research note issued to investors on Wednesday, November 19th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the biotechnology company will post earnings of ($0.05) per share for the year, up from their prior forecast of ($0.94). The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share. Cantor Fitzgerald also issued estimates for Arrowhead Pharmaceuticals’ FY2026 earnings at ($3.58) EPS.

Several other equities analysts have also commented on ARWR. TD Cowen raised shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a report on Monday, July 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 8th. Royal Bank Of Canada lifted their price target on Arrowhead Pharmaceuticals from $45.00 to $52.00 and gave the company an “outperform” rating in a report on Wednesday. The Goldman Sachs Group increased their price objective on Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the stock a “neutral” rating in a report on Thursday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $48.22.

Arrowhead Pharmaceuticals Stock Performance

ARWR stock opened at $38.09 on Friday. Arrowhead Pharmaceuticals has a 1 year low of $9.57 and a 1 year high of $43.69. The stock has a market capitalization of $5.27 billion, a price-to-earnings ratio of -29.76 and a beta of 1.27. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.87 and a current ratio of 4.87. The stock’s fifty day moving average is $36.73 and its two-hundred day moving average is $24.37.

Insider Activity at Arrowhead Pharmaceuticals

In related news, insider James C. Hamilton sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. Following the sale, the insider owned 212,122 shares of the company’s stock, valued at $7,424,270. The trade was a 8.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 50,000 shares of company stock worth $1,525,000 in the last quarter. 4.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ARWR. Keystone Financial Group bought a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth $276,000. CANADA LIFE ASSURANCE Co boosted its position in shares of Arrowhead Pharmaceuticals by 11.7% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 129,958 shares of the biotechnology company’s stock valued at $4,389,000 after purchasing an additional 13,653 shares during the period. Woodline Partners LP increased its position in shares of Arrowhead Pharmaceuticals by 34.0% in the third quarter. Woodline Partners LP now owns 1,000,158 shares of the biotechnology company’s stock worth $34,495,000 after acquiring an additional 254,002 shares in the last quarter. Virtus Advisers LLC grew its position in Arrowhead Pharmaceuticals by 581.5% during the 3rd quarter. Virtus Advisers LLC now owns 14,462 shares of the biotechnology company’s stock worth $499,000 after purchasing an additional 12,340 shares in the last quarter. Finally, Voloridge Investment Management LLC acquired a new position in Arrowhead Pharmaceuticals during the third quarter valued at $13,888,000. 62.61% of the stock is owned by institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.